{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:57:09Z","timestamp":1789016229812,"version":"build-2803163510"},"reference-count":158,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2023,6,3]]},"DOI":"10.1080\/17474086.2023.2184341","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T07:18:16Z","timestamp":1678346296000},"page":"417-433","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["New directions to develop therapies for people with hemophilia"],"prefix":"10.1080","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-5550","authenticated-orcid":false,"given":"Pooja","family":"Gogia","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Maimonides Medical Center, Brooklyn, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tarantino","sequence":"additional","affiliation":[{"name":"University of Illinois College of Medicine, and the Bleeding and Clotting Disorders Institute, Peoria, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schramm","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians University (LMU) Rudolf Marx Stiftung Munich, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Aledort","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Icahn School of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200106073442307"},{"key":"cit0002","unstructured":"Accessed on 2022 Sep 4. https:\/\/www.hemophilia.org\/bleeding-disorders-a-z\/overview\/history"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2013.10.020"},{"key":"cit0004","first-page":"1","volume-title":"Hematology Am Soc Hematol Educ Program","author":"Mannucci PM","year":"2002"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00780.x"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13747"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.239160"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12730"},{"key":"cit0009","first-page":"101011","volume":"23","author":"Di Minno G","year":"2022","journal-title":"Blood Rev"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01604"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002731"},{"issue":"12","key":"cit0012","volume":"16","author":"AD S","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"12","key":"cit0013","first-page":"CD004449","volume":"2015","author":"Matino D","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1551356"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616569"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.670526"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001542"},{"key":"cit0018","unstructured":"https:\/\/hemophilianewstoday.com\/2021\/03\/01\/fitusiran-dosing-phase-3-trials-reduced-to-lower-risk-of-blood-clots (Accessed on 2022 Sep 4th)."},{"issue":"6","key":"cit0019","first-page":"479","volume":"17","author":"Aledort L","year":"2019","journal-title":"Blood Transfus"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-669234"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000007"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168377"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1070476"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00546.x"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.9.s1.17.x"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1994.tb00815.x"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00483.x"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718796429"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-367813"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02931.x"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0941"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.232132"},{"key":"cit0033","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761083s002s004lbl.pdf (Accessed on 2022 Oct 4)."},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001140"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(96)80063-1"},{"key":"cit0036","unstructured":"US Food and Drug Administration [internet]. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products (cited 2022 Sep 15)."},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(96)80064-3"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655957"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.05.005"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1657535"},{"issue":"9","key":"cit0041","first-page":"2428","volume":"83","author":"Bray GL","year":"1994","journal-title":"Blood"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00191.x"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12952"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13647"},{"issue":"2","key":"cit0045","first-page":"33","volume":"35","author":"White G","year":"1998","journal-title":"Semin Hematol"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3600"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2283"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12228"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00261"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613925"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208024"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516437"},{"key":"cit0053","unstructured":"US Food and Drug Administration [internet] ELOCTATE prescribing information. 2017. [Accessed on 2022 Feb 09]. Available at: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/UCM400192.pdf."},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-382846"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529974"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12911"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12766"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-10-0780"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13413"},{"issue":"1","key":"cit0060","first-page":"S29","volume":"32","author":"Turecek PL","year":"2012","journal-title":"Hamostaseologie"},{"key":"cit0061","unstructured":"US Food and Drug Administration [internet]. ADYNOVATE prescribing information; 2016. Accessed on 2022 Feb 07. Available at: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/UCM472594.pdf"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13807"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630897"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12506"},{"key":"cit0065","unstructured":"US Food and Drug Administration [internet]. JIVI Antihemophilic Factor (Recombinant) PEGylated-aucl prescribing information; 2018. Accessed on 2022 Jan 11. Available at: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/UCM618979.pdf"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13561"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2019.08.023"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13597"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.01.015"},{"key":"cit0070","unstructured":"US Food and Drug Administration [internet]. February 19, 2019 Approval Letter - ESPEROCT. BL 125671\/0. Accessed on 2022 Oct 10. Available at: https:\/\/www.fda.gov\/media\/120350\/download"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12161"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-03-0166"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239665"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-367003"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305074"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30193-4"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-696104"},{"key":"cit0078","unstructured":"https:\/\/www.fda.gov\/media\/96526\/download. cited 2022 Sep 15."},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(13)70152-X"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-336172"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-335596"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-573055"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2942"},{"key":"cit0084","unstructured":"https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm459987.pdf (Accessed on Nov 29, 2022)."},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511769"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S288283"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1909742"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S205310"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.03.002"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-713289"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26018"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010331"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00551.x"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147647"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104205"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113708"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119913"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112471"},{"key":"cit0102","volume-title":"Front Immunol","volume":"17","author":"Anti-AAV WT","year":"2021"},{"issue":"2","key":"cit0103","volume":"5","author":"Schmidt M","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.2741\/4324"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1588"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001292"},{"key":"cit0107","unstructured":"FDA grants priority review to efanesoctocog alfa for people with hemophilia A. pdf (Accessed 2022 Nov 3)."},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002699"},{"key":"cit0109","unstructured":"Spira J, Widlund L, \u00d6sterberg T, et al. Pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration of factor VIII of factor IX. International patent application: US patent US5925739A, European patent EP0772452. 1995 March 30. https:\/\/patentimages.storage.googleapis.com\/ec\/59\/6c\/cfe13d59588396\/US5925739.pdf"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02735.x"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.56.082103.104713"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1211\/0022357001774651"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006468"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14660"},{"issue":"9","key":"cit0115","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1182\/blood-2017-07-793356","volume":"130","author":"Solecka-Wituska BA","year":"2017","journal-title":"Blood"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3757.3757"},{"issue":"1","key":"cit0117","first-page":"Abstract 87","volume":"130","author":"Csh WY","year":"2017","journal-title":"Blood"},{"key":"cit0118","unstructured":"Catalyst Biosciences provides update on CB 2679d\/ISU304 factor IX clinical program in Hemophilia B. http:\/\/ir.catalystbiosciences.com\/phoenix.zhtml. cited 2022 Oct 19"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14315"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12576"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32722-7"},{"key":"cit0122","unstructured":"Hashim MA, Yamaguchi A, Vo AT, et al. Orally delivered factor VIII restores hemostasis in a hemophilia A dog. ISTH 2021 Congress. Abstract number: OC 48.4."},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2015.08.004"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.11.009"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15682"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148571"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18495"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12438"},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15244"},{"key":"cit0130","unstructured":"http:\/\/investors.alnylam.com\/releasedetail.cfm?ReleaseID=1039464 (Accessed on 2022 Sep 07"},{"key":"cit0131","unstructured":"https:\/\/hemophilianewstoday.com\/2021\/03\/01\/fitusiran-dosing-phase-3-trials-reduced-to-lower-risk-of-blood-clots (Accessed on 2022 Nov 18"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15270"},{"issue":"2","key":"cit0133","first-page":"LBA","volume":"138","author":"Srivastava A","year":"2021","journal-title":"Blood"},{"key":"cit0134","first-page":"2","volume":"5","author":"Bhagunde P","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C100123200"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a134583"},{"key":"cit0137","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718635"},{"key":"cit0138","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16720-9"},{"key":"cit0139","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-800326"},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2010.155"},{"key":"cit0141","unstructured":"Laffan MA, Rangarajan S, Lester W, et al. Hemostatic results for up to 6 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A. Presentation OC 21.2. ISTH Congress, 9-13 Jul, 2022."},{"key":"cit0142","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01751-0"},{"key":"cit0143","unstructured":"Chapin JC, Ayash-Rashkovsky M, Kenniston J, et al. A translational analysis of immune components in peripheral blood from severe hemophilia A patients treated with TAK-754, an AAV8 vector with a codon-optimized B-domain deleted factor VIII transgene. Presentation PB0211. ISTH Congress, 9-13 Jul, 2022."},{"key":"cit0144","unstructured":"https:\/\/investors.biomarin.com\/2022-08-24-First-Gene-Therapy-for-Adults-with-Severe-Hemophilia-A,BioMarins-ROCTAVIAN-TM-valoctocogene-roxaparvovec-Approved-by-European-Commission-EC (Accessed on 2022 Oct 19"},{"key":"cit0145","unstructured":"https:\/\/www.fda.gov\/media\/163466\/download. cited 2023 Jan 30."},{"key":"cit0146","doi-asserted-by":"crossref","unstructured":"Itzler R, Miller J, Robson R, et al. Improvements in health-related quality of life in adults with severe or moderately severe hemophilia B after receiving etranacogene dezaparvovec gene therapy. Presentation OC 01.02. ISTH Congress, 9-13 July, 2022.","DOI":"10.1055\/s-0042-1760525"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166135"},{"key":"cit0148","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908490"},{"key":"cit0149","unstructured":"https:\/\/hemophilianewstoday.com\/2020\/12\/11\/high-dose-gene-therapy-sb-525-fviii-levels-prevents-bleeds-alta-trial-data\/ (Accessed on 2022 Nov 17"},{"key":"cit0150","unstructured":"Young G, Chowdary P, Barton S, et al. Results from B-LIEVE, a phase 1\/2 dose confirmation study of FLT180a AAV gene therapy in patients with hemophilia B. Presentation PB0213. ISTH Congress, 9-13 Jul, 2022."},{"key":"cit0151","unstructured":"Lawton S, Manson M, Fan M, et al. Liver sinusoidal endothelial cells targeted with ultrasound mediated gene delivery shows long-term FVIII expression in hemophilia A mice. Presentation OC 12.5. ISTH Congress, 9-13 Jul, 2022."},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.20"},{"key":"cit0153","unstructured":"Chen C, Cai X, Miao C, et al. Rescue of the endogenous FVIII expression in hemophilia A mice using CRISPR\/ Cas9 mRNA LNPs. Presentation OC 12.3. ISTH Congress, 9-13 Jul, 2022."},{"key":"cit0154","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018027219"},{"key":"cit0155","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911298"},{"key":"cit0156","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02346.x"},{"key":"cit0157","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3773"},{"key":"cit0158","unstructured":"Accessed on 2022 Sept 25. https:\/\/www.hemophilia.org\/news\/sigilon-announces-a-priority-shift-in-light-of-clinical-trial-setbacks"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2023.2184341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T01:05:19Z","timestamp":1729040719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2023.2184341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":158,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,3]]}},"alternative-id":["10.1080\/17474086.2023.2184341"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2023.2184341","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-11-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}